FDA issues another biosimilars Q&A guidance

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

FDA issues another biosimilars Q&A guidance

Home/Guidelines | Posted 22/05/2015 0 Post your comment

On 13 May 2015, the US Food and Drug Administration (FDA) issued another question and answer guidance document for biosimilar applications in the US. The draft guidance contains a question on the issue of interchangeability with reference biologicals.

FDA also recently finalized three other guidelines in April 2015 [1]. FDA first published the three draft guidelines in February 2012 [2], following the signing into law of the biosimilars pathway as part of the Biologics Price Competition and Innovation Act (BPCI) in 2010.

The agency has now issued a draft guidance on additional questions and answers on biosimilars. The guidance provides new and revised questions and answers. It also includes certain original questions and answers that have not yet been finalized.

Biosimilars: additional questions and answers regarding implementation of the Biologics Prices Competition and Innovation Act of 2009
Date: May 2015
www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm273001.pdf

One of the new questions concerns demonstration of interchangeability, which FDA says will be possible to determine in an original biosimilar application. Although, rather disappointingly, the agency also states that ‘at this time, it would be difficult as a scientific matter for a prospective biosimilar applicant to establish interchangeability in an original 351(k) application given the statutory standard for interchangeability and the sequential nature of that assessment.’ FDA says that it ‘is continuing to consider the type of information sufficient to enable FDA to determine that a biological product is interchangeable with the reference product.’

The draft guidance document is being distributed for comment.

What happens next?
Comments and suggestions regarding this notice can be submitted to www.regulations.gov or to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852, USA, within 60 days of publication (13 May 2015) in the Federal Register of the notice announcing the availability of the draft guidance. That means that all comments and suggestions should be submitted by 12 July 2015.

Interchangeability not covered in FDA draft biosimilar guidance

US guidelines for biosimilars

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA finalizes biosimilars guidelines [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www.gabionline.net/Guidelines/FDA-finalizes-biosimilars-guidelines
2. GaBI Online - Generics and Biosimilars Initiative. FDA finally issues draft biosimilar guidance [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www.gabionline.net/Guidelines/FDA-finally-issues-draft-biosimilar-guidance

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Federal Register, FDA